Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays cut their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Stock Down 0.8 %

CLLS stock opened at $1.56 on Monday. The company has a market cap of $86.71 million, a price-to-earnings ratio of -1.20 and a beta of 3.09. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The business’s 50-day moving average is $1.87 and its two-hundred day moving average is $2.04. Cellectis has a fifty-two week low of $1.53 and a fifty-two week high of $3.55.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The business had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same quarter last year, the company earned ($0.31) EPS. As a group, analysts forecast that Cellectis will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Cellectis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLLS. Long Focus Capital Management LLC increased its stake in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after buying an additional 12,467 shares during the period. First Affirmative Financial Network purchased a new stake in Cellectis in the 3rd quarter worth $45,000. Finally, XTX Topco Ltd bought a new stake in Cellectis during the second quarter valued at about $29,000. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.